



BSW Formulary Updates and Recent Decisions – March 2024

New additions to BSWformulary and Change in Traffic Light Status

- [Bempedoic acid monotherapy](#) – change from **amber** to **green**. Use of bempedoic acid as **monotherapy** is within the product license for Nilemdo® but outside of current NICE recommendations. In patients with true intolerance to ezetimibe, the use of bempedoic acid as monotherapy is ONLY supported locally where there are no other suitable alternative treatment options.
- [Candesartan for migraine prophylaxis](#) – change from **amber** to **green** in line with recently updated [BSW primary care migraine treatment pathway](#) BASH patient info leaflet [here](#)
- [Carbimazole](#) and [sulfasalazine](#) entries aligned as **amber** and **amber (with SCA)** respectively.

New and Updated Shared Care Agreements and Prescribing Guidance

- **UPDATE** – [Denosumab for osteoporosis in adults SCA](#) – Information added regarding stopping and switching treatment, highlighting the risks of an abrupt stop of treatment.
- **NEW** – [BSW Continence and Urology Products Formulary](#) – This list of continence and urology products has been compiled in consultation with continence leads across BSW. Further work is underway to consider specialist areas such as intermittent self-catheterisation and review opportunities for cost-savings.
- **UPDATE** – [BSW Management of Infection Guidance for Primary Care](#) – Minor update to antibiotic choice in the epididymo-orchitis section, as per CKS.
- **UPDATE** - [Treatment of Alzheimer's Disease SCA](#) Minor update to contact details section

Minor amendments to Netformulary

- [Tirzepatide \(Mounjaro®\) 2.5mg/0.6ml and 5mg/0.6ml solution for injection 2.4ml pre-filled KwikPen®](#) now available for prescribing in line with [NICE TA924](#) and [local guidance](#). **Green** TLS.

What the BSW CCG formulary team are currently working on

- Aligning TLS and SCAs for alfacalcidol use across BSW.
- An application for the use of cytosine 1.5mg tablets for use in smoking cessation.
- Working with our commissioners to review tier 3 obesity services in order to provide the semaglutide option in line with NICE TA875.
- Working as a collaborative Integrated Care System diabetes group to implement Hybrid Closed Loop system provision in line with NICE TA943.
- Supporting the primary care team with a BSW LES review.
- Reviewing the current BSW Sativex policy

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net